USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6

• 收藏
• 分享

专利权人:

Biocon Limited

发明人:

Pradip NAIR,Arindam SAHA,Ravindra Belavinakodige SADASHIVARAO,Usha BUGHANI,Ramakrishnan MELARKODE

申请号：

US16387442

公开号：

US20190248913A1

申请日:

2019.04.17

申请国别(地区):

US

年份:

2019

代理人:

摘要：

The present invention discloses a key mechanism of action of Itolizumab that involves a decrease in an activating ALCAM-CD6 co stimulatory signal by directly reducing CD6 hyperphosphorylation and preventing the docking of key molecules associated with T cell activation and signaling.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/